nach oben

Journal of Neuro-Oncology

Erschienen in:

22.04.2017 | Topic Review

Dendritic cell based vaccination strategy: an evolving paradigm

verfasst von: Anna C. Filley, Mahua Dey

Erschienen in: Journal of Neuro-Oncology | Ausgabe 2/2017

Einloggen, um Zugang zu erhalten

Abstract

Malignant gliomas (MG), tumors of glial origin, are the most commonly diagnosed primary intracranial malignancies in adults. Currently available treatments have provided only modest improvements in overall survival and remain limited by inevitable local recurrence, necessitating exploration of novel therapies. Among approaches being investigated, one of the leading contenders is immunotherapy, which aims to modulate immune pathways to stimulate the selective destruction of malignant cells. Dendritic cells (DCs) are potent initiators of adaptive immune responses and therefore crucial players in the development and success of immunotherapy. Clinical trials of various DC-based vaccinations have demonstrated the induction of anti-tumor immune responses and prolonged survival in the setting of many cancers. In this review, we summarize current literature regarding DCs and their role in the tumor microenvironment, their application and current clinical use in immunotherapy, current challenges limiting their efficacy in anti-cancer therapy, and future avenues for developing successful anti-tumor DC-based vaccines.

Banchereau J, Briere F, Caux C, Davoust J, Lebecque S, Liu YG, Pulendran B, Palucka K (2000) Immunobiology of dendritic cells. Annu Rev Immunol 18:767–811CrossRefPubMed

Timmerman JM, Levy R (1999) Dendritic cell vaccines for cancer immunotherapy. Annu Rev Med 5:507–529CrossRef

Zou W (2005) Immunosuppressive networks in the tumor environment and their therapeutic relevance. Nat Rev Cancer 5(4):263–274CrossRefPubMed

Rabinovich GA, Gabrilovich D, Sotomayor EM (2007) Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol 25:267–296CrossRefPubMedPubMedCentral

Steinman RM, Dhodapkar M (2001) Active immunization against cancer with dendritic cells: the near future. Int J Cancer 94(4):459–473CrossRefPubMed

Steinman RM, Hawiger D, Nussenzweig MC (2003) Tolerogenic dendritic cells. Annu Rev Immunol 21:685–711CrossRefPubMed

Lutz MB, Schuler G (2002) Immature, semi-mature and fully mature dendritic cells: which signals induce tolerance or immunity? Trends Immunol 23(9):445–449CrossRefPubMed

Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K et al (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10(5):459–466CrossRefPubMed

Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987–996CrossRefPubMed

10.

Heufler C, Koch F, Stanzl U, Topar G, Wysocka M, Trinchieri G, Enk A, Steinman RM, Romani N, Schuler G (1996) Interleukin-12 is produced by dendritic cells and mediates T helper 1 development as well as interferon-gamma production by T helper 1 cells. Eur J Immunol 26(3):659–668CrossRefPubMed

11.

Kaiko GE, Horvat JC, Beagley KW, Hansbro PM (2008) Immunological decision-making: how does the immune system decide to mount a helper T-cell response? Immunology 123(3):326–338CrossRefPubMedPubMedCentral

12.

Candolfi M, King GD, Yagiz K, Curtin JF, Mineharu Y, Muhammad AKMG, Foulad D, Kroeger KM, Barnett N, Josien R et al (2012) Plasmacytoid dendritic cells in the tumor microenvironment: immune targets for glioma therapeutics. Neoplasia 14(8):757–770CrossRefPubMedPubMedCentral

13.

O’Neill DW, Adams S, Bhardwaj N (2004) Manipulating dendritic cell biology for the active immunotherapy of cancer. Blood 104(8):2235–2246CrossRefPubMed

14.

Dhodapkar MV, Steinman RM, Krasovsky J, Munz C, Bhardwaj N (2001) Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J Exp Med 193(2):233–238CrossRefPubMedPubMedCentral

15.

Ghosh P, Komschlies KL, Cippitelli M, Longo DL, Subleski J, Ye JP, Sica A, Young HA, Wiltrout RH, Ochoa AC (1995) Gradual loss of T-helper 1 populations in spleen of mice during progressive tumor growth. J Natl Cancer Inst 87(19):1478–1483CrossRefPubMed

16.

Grauer OM, Nierkens S, Bennink E, Toonen LWJ, Boon L, Wesseling P, Sutmuller RPM, Adema GJ (2007) CD4+ FoxP3+ regulatory T cells gradually accumulate in gliomas during tumor growth and efficiently suppress antiglioma immune responses in vivo. Int J Cancer 121(1):95–105CrossRefPubMed

17.

Boon T, Coulie PG, vandenEynde (1997) Tumor antigens recognized by T cells. Immunol Today 18(6):267–268CrossRefPubMed

18.

Stewart B, Wild CP (2014) World cancer report 2014. International agency for research on cancer. WHO, Geneva

19.

Melief CJM (2008) Cancer immunotherapy by dendritic cells. Immunity 29(3):372–383CrossRefPubMed

20.

Yu H, Pardoll D, Jove R (2009) STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 9(11):798–809CrossRefPubMedPubMedCentral

21.

Kalinski P, Okada H (2010) Polarized dendritic cells as cancer vaccines: directing effector-type T cells to tumors. Semin Immunol 22(3):173–182CrossRefPubMedPubMedCentral

22.

Dix AR, Brooks WH, Roszman TL, Morford LA (1999) Immune defects observed in patients with primary malignant brain tumors. J Neuroimmunol 100(1–2):216–232CrossRefPubMed

23.

Walker DG, Chuah T, Rist MJ, Pender MP (2006) T-cell apoptosis in human glioblastoma multiforme: implications for immunotherapy. J Neuroimmunol 175(1–2):59–68CrossRefPubMed

24.

Liau LM, Prins RM, Kiertscher SM, Odesa SK, Kremen TJ, Giovannone AJ, Lin JW, Chute DJ, Mischel PS, Cloughesy TF et al (2005) Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment. Clin Cancer Res 11(15):5515–5525. doi:10.1158/1078-0432.CCR-05-0464 CrossRefPubMed

25.

Zhai L, Lauing KL, Chang AL, Dey M, Qian J, Cheng Y, Lesniak MS, Wainwright DA (2015) The role of IDO in brain tumor immunotherapy. J Neurooncol 123(3):395–403CrossRefPubMed

26.

Dey M, Chang AL, Miska J, Wainwright DA, Ahmed AU, Balyasnikova IV, Pytel P, Han Y, Tobias A, Zhang LJ et al (2015) Dendritic cell-based vaccines that utilize myeloid rather than plasmacytoid cells offer a superior survival advantage in malignant glioma. J Immunol 195(1):367–376CrossRefPubMedPubMedCentral

27.

Palucka K, Banchereau J (2012) Cancer immunotherapy via dendritic cells. Nat Rev Cancer 12(4):265–277CrossRefPubMedPubMedCentral

28.

Prins RM, Soto H, Konkankit V, Odesa SK, Eskin A, Yong WH, Nelson SF, Liau LM (2011) Gene expression profile correlates with T cell infiltration and relative survival in glioblastoma patients vaccinated with dendritic cell immunotherapy. Clin Cancer Res 17(6):1603–1615. doi:10.1158/1078-0432.CCR-10-2563 CrossRefPubMed

29.

Prins RM, Wang XY, Soto H, Young E, Lisiero DN, Fong B, Everson R, Yong WH, Lai A, Li G et al (2013) Comparison of glioma-associated antigen peptide-loaded versus autologous tumor lysate-loaded dendritic cell vaccination in malignant glioma patients. J Immunother 36(2):152–157. doi:10.1097/CJI.0b013e3182811ae4 CrossRefPubMedPubMedCentral

30.

Casares N, Arribillaga L, Sarobe P, Dotor J, de Cerio ALD, Melero I, Prieto J, Borras-Cuesta F, Lasarte JJ (2003) CD4(+)/CD25(+) regulatory cells inhibit activation of tumor-primed CD4(+) T cells with IFN-gamma-dependent antiangiogenic activity, as well as long-lasting tumor immunity elicited by peptide vaccination. J Immunol 171(11):5931–5939CrossRefPubMed

31.

Rech AJ, Vonderheide RH (2009) Clinical use of anti-CD25 antibody daclizumab to enhance immune responses to tumor antigen vaccination by targeting regulatory T cells. Ann N Y Acad Sci 1174:99–106CrossRefPubMed

32.

Ashley DM, Faiola B, Nair S, Hale LP, Bigner DD, Gilboa E (1997) Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors. J Exp Med 186(7):1177–1182CrossRefPubMedPubMedCentral

33.

Liau LM, Black KL, Prins RM, Sykes SN, DiPatre PL, Cloughesy TF, Becker DP, Bronstein JM (1999) Treatment of intracranial gliomas with bone marrow-derived dendritic cells pulsed with tumor antigens. J Neurosurg 90(6):1115–1124CrossRefPubMed

34.

HeimbergerAB, Archer GE, Crotty LE, McLendon RE, Friedman AH, Friedman HS, Bigner DD, Sampson JH (2002) Dendritic cells pulsed with a tumor-specific peptide induce long-lasting immunity and are effective against murine intracerebral melanoma. Neurosurgery 50(1):158–164

35.

Hsu FJ, Benike C, Fagnoni F, Liles TM, Czerwinski D, Taidi B, Engleman EG, Levy R (1996) Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 2(1):52–58. doi:10.1038/nm0196-52 CrossRefPubMed

36.

Nestle FO, Alijagic S, Gilliet M, Sun YS, Grabbe S, Dummer R, Burg G, Schadendorf D (1998) Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 4(3):328–332CrossRefPubMed

37.

Murphy GP, Tjoa BA, Simmons SJ, Jarisch J, Bowers VA, Ragde H, Rogers M, Elgamal A, Kenny GM, Cobb OE et al (1999) Infusion of dendritic cells pulsed with HLA-A2- specific prostate-specific membrane antigen peptides: a phase II prostate cancer vaccine trial involving patients with hormone-refractory metastatic disease. Prostate 38(1):73–78CrossRefPubMed

38.

Thurner B, Haendle I, Roder C, Dieckmann D, Keikavoussi P, Jonuleit H, Bender A, Maczek C, Schreiner D, von den Dresch P et al (1999) Vaccination with Mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med 190(11):1669–1678CrossRefPubMedPubMedCentral

39.

Mackensen A, Herbst B, Chen JL, Kohler G, Noppen C, Herr W, Spagnoli GC, Cerundolo V, Lindemann A (2000) Phase I study in melanoma patients of a vaccine with peptide-pulsed dendritic cells generated in vitro from CD34(+) hematopoietic progenitor cells. Int J Cancer 86(3):385–392CrossRefPubMed

40.

Fong L, Hou YF, Rivas A, Benike C, Yuen A, Fisher GA, Davis MM, Engleman EG (2001) Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy. Proc Natl Acad Sci USA 98(15):8809–8814CrossRefPubMedPubMedCentral

41.

Banchereau J, Palucka AK, Dhodapkar M, Burkeholder S, Taquet N, Rolland A, Taquet S, Coquery S, Wittkowski KM, Bhardwaj N et al (2001) Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. Cancer Res 61(17):6451–6458PubMed

42.

Schuler-Thurner B, Schultz ES, Berger TG, Weinlich G, Ebner S, Woerl P, Bender A, Feuerstein B, Fritsch PO, Romani N et al (2002) Rapid induction of tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells. J Exp Med 195(10):1279–1288CrossRefPubMedPubMedCentral

43.

Timmerman JM, Czerwinski DK, Davis TA, Hsu FJ, Benike C, Hao ZM, Taidi B, Rajapaksa R, Caspar CB, Okada CY et al (2002) Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood 99(5):1517–1526CrossRefPubMed

44.

Ferrara A, Nonn M, Sehr P, Schreckenberger C, Pawlita M, Durst M, Schneider A, Kaufmann AM et al (2003) Dendritic cell-based tumor vaccine for cervical cancer II: results of a clinical pilot study in 15 individual patients. J Cancer Res Clin Oncol 129(9):521–530CrossRefPubMed

45.

Salcedo M, Bercovici, Taylor R, Vereecken P, Massicard S, Duriau D, Vernel-Pauillac F, Boyer A, Baron-Bodo V, Mallard E et al (2006) Vaccination of melanoma patients using dendritic cells loaded with an allogeneic tumor cell lysate. Cancer Immunol Immunother 55(7):819–829CrossRefPubMed

46.

Palucka AK, Ueno H, Connolly J, Kerneis-Norvell F, Blanck JP, Johnston DA, Fay J, Banchereau J (2006) Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8(+) T-cell immunity. J Immunother 29(5):545–557CrossRefPubMed

47.

Wierecky J, Muller MR, Wirths S, Halder-Oehler E, Dorfel D, Schmidt SM, Hantschel M, Brugger W, Schroder S, Horder MS et al (2006) Immunologic and clinical responses after vaccinations with peptide-pulsed dendritic cells in metastatic renal cancer patients. Cancer Res 66(11):5910–5918. doi:10.1158/0008-5472.CAN-05-3905 CrossRefPubMed

48.

Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB et al (2010) Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363(5):411–422. doi:10.1056/NEJMoa1001294 CrossRefPubMed

49.

Liau LM, Black KL, Martin NA, Sykes SN, Bronstein JM, Jouben-Steele L, Mischel PS, Belldegrun A, Cloughesy TF (2000) Treatment of a patient by vaccination with autologous dendritic cells pulsed with allogeneic major histocompatibility complex class I-matched tumor peptides. Case report. Neurosurg Focus 9(6):e8CrossRefPubMed

50.

Yu JS, Wheeler CJ, Zeltzer PM, Ying H, Finger DN, Lee PK, Yong WH, Incardona F, Thompson RC, Riedinger MS et al (2001) Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration. Cancer Res 61(3):842–847PubMed

51.

Kikuchi T, Akasaki Y, Irie M, Homma S, Abe T, Ohno T (2001) Results of a phase I clinical trial of vaccination of glioma patients with fusions of dendritic and glioma cells. Cancer Immunol Immunother 50(7):337–344. doi:10.1007/s002620100205 CrossRefPubMed

52.

Yamanaka R, Abe T, Yajima N, Tsuchiya N, Tsuchiya N, Homma J, Kobayashi T, Narita M, Takahashi M, Tanaka R (2003) Vaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune responses: results of a clinical phase I/II trial. Br J Cancer 89(7):1172–1179CrossRefPubMedPubMedCentral

53.

Yu JS, Liu G, Ying H, Yong WH, Black KL, Wheeler CJ (2004) Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma. Cancer Res 64(14):4973–4979CrossRefPubMed

54.

Rutkowski S, DeVleeschouwer S, Kaempgen E, Wolff JEA, Kuhl J, Demaerel P, Warmuth-Metz M, Flamen P, Van Calenbergh F, Plets C et al (2004) Surgery and adjuvant dendritic cell-based tumour vaccination for patients with relapsed malignant glioma, a feasibility study. Br J Cancer 91(9):1656–1662. doi:10.1038/sj.bjc.6602195 PubMedPubMedCentral

55.

Kikuchi T, Akasaki Y, Abe T, Fukuda T, Saotome H, Ryan JL, Kufe DW, Ohno T (2004) Vaccination of glioma patients with fusions of dendritic and glioma cells and recombinant human interleukin 12. J Immunother 27(6):452–459. doi:10.1097/00002371-200411000-00005 CrossRefPubMed

56.

Yamanaka R, Homma J, Yajima N, Tsuchiya N, Sano M, Kobayashi T, Yoshida S, Abe T, Narita M, Takahashi M et al (2005) Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: results of a clinical phase I/II trial. Clin Cancer Res 11(11):4160–4167CrossRefPubMed

57.

Wheeler CJ, Black KL, Liu G, Mazer M, Zhang XX, Pepkowitz S, Goldfinger D, Ng HS, Irvin D, Yu JS (2008) Vaccination elicits correlated immune and clinical responses in glioblastoma multiforme patients. Cancer Res 68(14):5955–5964CrossRefPubMed

58.

Walker DG, Laherty R, Tomlinson FH, Chuah T, Schmidt C (2008) Results of a phase I dendritic cell vaccine trial for malignant astrocytoma: potential interaction with adjuvant chemotherapy. J Clin Neurosci 15(2):114–121. doi:10.1016/j.jocn.2007.08.007 CrossRefPubMed

59.

Ardon H, Van Gool S, Lopes IS, Maes W, Sciot R, Wilms G, Demaerel P, Bitjttebier P, Claes L, Goffin J et al (2010) Integration of autologous dendritic cell-based immunotherapy in the primary treatment for patients with newly diagnosed glioblastoma multiforme: a pilot study. J Neurooncol 99(2):261–272. doi:10.1007/s11060-010-0131-y CrossRefPubMed

60.

Fadul CE, Fisher JL, Hampton TH, Lallana EC, Li Z, Gui J, Szczepiorkowski ZM, Tosteson TD, Rhodes CH, Wishart HA et al (2011) Immune response in patients with newly diagnosed glioblastoma multiforme treated with intranodal autologous tumor lysate-dendritic cell vaccination after radiation chemotherapy. J Immunother 34(4):382–389. doi:10.1097/CJI.0b013e318215e300 CrossRefPubMedPubMedCentral

61.

Okada H, Kalinski P, Ueda R, Hoji A, Kohanbash G, Donegan TE, Mintz AH, Engh JA, Bartlett DL, Brown CK et al (2011) Induction of CD8(+) T-Cell responses against novel glioma–associated antigen peptides and clinical activity by vaccinations with alpha-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma. J Clin Oncol 29(3):330–336. doi:10.1200/JCO.2010.30.7744 CrossRefPubMed

62.

Chang CN, Huang YC, Yang DM, Kikuta K, Wei KJ, Kubota T, Yang WK (2011) A phase I/II clinical trial investigating the adverse and therapeutic effects of a postoperative autologous dendritic cell tumor vaccine in patients with malignant glioma. J Clin Neurosci 18(8):1048–1054CrossRefPubMed

63.

Ardon H, Van Gool SW, Verschuere T, Maes W, Fieuws S, Sciot R, Wilms G, Demaerel P, Goffin J, Van Calenbergh F et al (2012) Integration of autologous dendritic cell-based immunotherapy in the standard of care treatment for patients with newly diagnosed glioblastoma: results of the HGG-2006 phase I/II trial. Cancer Immunol Immunother 61(11):2033–2044. doi:10.1007/s00262-012-1261-1 CrossRefPubMed

64.

Phuphanich S, Wheeler CJ, Rudnick JD, Mazer M, Wang HQ, Nuno MA, Richardson JE, Fan XM, Ji JF, Chu RM et al (2013) Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma. Cancer Immunol Immunother 62(1):125–135. doi:10.1007/s00262-012-1319-0 CrossRefPubMed

65.

Bonifaz L, Bonnyay D, Mahnke K, Rivera M, Nussenzweig MC, Steinman RM (2002) Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8(+) T cell tolerance. J Exp Med 196(12):1627–16338. doi:10.1084/jem.20021598 CrossRefPubMedPubMedCentral

66.

Kastenmuller W, Kastenmuller K, Kurts C, Seder RA (2014) Dendritic cell-targeted vaccines—hope or hype? Nat Rev Immunol 14(10):705–711. doi:10.1038/nri3727 CrossRefPubMed

67.

Thurner B, Roder C, Dieckmann D, Heuer H, Kruse M, Glaser A, Keikavoussi P, Kampgen E, Bender A, Schuler G (1999) Generation of large numbers of fully mature and stable dendritic cells from leukapheresis products for clinical application. J Immunol Methods 223(1):1–15. doi:10.1016/S0022-1759(98)00208-7 CrossRefPubMed

68.

Schreibelt G, Benitez-Ribas D, Schuurhuis D, Lambeck AJA, van Hout-Kuijer M, Schaft N, Punt CJ, Figdor CG, Adema GJ, de Vries IJM (2010) Commonly used prophylactic vaccines as an alternative for synthetically produced TLR ligands to mature monocyte-derived dendritic cells. Blood 116(4):564–574. doi:10.1182/blood-2009-11-251884 CrossRefPubMed

69.

Kalinski P, Muthuswamy R, Urban J (2013) Dendritic cells in cancer immunotherapy: vaccines and combination immunotherapies. Expert Rev Vaccines 12(3):285–295. doi:10.1586/ERV.13.22 CrossRefPubMed

70.

Engell-Noerregaard L, Hansen TH, Andersen MH, Straten PT, Svane IM (2009) Review of clinical studies on dendritic cell-based vaccination of patients with malignant melanoma: assessment of correlation between clinical response and vaccine parameters. Cancer Immunol Immunother 58(1):1–14. doi:10.1007/s00262-008-0568-4 CrossRefPubMed

71.

Wimmers F, Schreibelt G, Skold AE, Figdor CG, De Vries IJM (2014) Paradigm shift in dendritic cell-based immunotherapy: from in vitro generated monocyte-derived DCs to naturally circulating DC subsets. Front Immunol. doi:10.3389/fimmu.2014.00165 PubMedPubMedCentral

72.

Derer A, Frey B, Fietkau R, Gaipl U (2016) Immune-modulating properties of ionizing radiation: rationale for the treatment of cancer by combination radiotherapy and immune checkpoint inhibitors. Cancer Immunol Immunother 65(7):779–786. doi:10.1007/s00262-015-1771-8 CrossRefPubMed

73.

Nikitina EY, Gabrilovich DI (2001) Combination of γ-irradiation and dendritic cell administration induces a potent antitumor response in tumor-bearing mice: approach to treatment of advanced stage cancer. Int J Cancer 94(6):825–833CrossRefPubMed

74.

Prins RM, Craft N, Bruhn KW, Khan-Farooqi H, Koya RC, Stripecke R, Miller JK, Liau LM (2006) The TLR-7 agonist, imiquimod, enhances dendritic cell survival and promotes tumor antigen-specific T cell priming: relation to central nervous system antitumor immunity. J Immunol 176(1):157–164CrossRefPubMed

75.

Vom Berg J, Vrohlings M, Haller S, Haimovici A, Kulig P, Sledzinska A, Weller M, Becher B (2013) Intratumoral IL-12 combined with CTLA-4 blockade elicits T cell–mediated glioma rejection. J Exp Med 210(13):2803–2811. doi:10.1084/jem.20130678 CrossRefPubMedPubMedCentral

76.

Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363(8):711–723. doi:10.1056/NEJMoa1003466 CrossRefPubMedPubMedCentral

77.

Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, Stankevich E, Pons A, Salay TM, McMiller TL et al (2010) Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 28(19):3167–3175. doi:10.1200/JCO.2009.26.7609 CrossRefPubMedPubMedCentral

78.

Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, Segal NH, Ariyan CE, Gordon RA, Reed K et al (2013) Nivolumab plus Ipilimumab in advanced melanoma. N Engl J Med 369(2):122–133. doi:10.1056/NEJMoa1302369 CrossRefPubMed

Titel: Dendritic cell based vaccination strategy: an evolving paradigm
verfasst von: Anna C. Filley
Mahua Dey
Publikationsdatum: 22.04.2017
Verlag: Springer US
Erschienen in: Journal of Neuro-Oncology / Ausgabe 2/2017
Print ISSN: 0167-594X
Elektronische ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-017-2446-4

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

18.04.2024 | Arterielle Hypertonie | Nachrichten

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Dendritic cell based vaccination strategy: an evolving paradigm

Abstract

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Spinale Muskelatrophie: Neugeborenen-Screening lohnt sich

Manche Gestagene können das Risiko für Meningeome erhöhen

Parkinson: Größere Studie bestätigt Genauigkeit von Hauttest

Update Neurologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2017

Precision knockdown of EGFR gene expression using radio frequency electromagnetic energy

A phase I trial of concurrent sorafenib and stereotactic radiosurgery for patients with brain metastases

Is mortality due to primary malignant brain and other central nervous system tumors decreasing?

SPECT imaging and radionuclide therapy of glioma using 131I labeled Buthus martensii Karsch chlorotoxin

Atypical and anaplastic meningioma: outcomes in a population based study

Functional analysis of the DEPDC1 oncoantigen in malignant glioma and brain tumor initiating cells

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Spinale Muskelatrophie: Neugeborenen-Screening lohnt sich

Manche Gestagene können das Risiko für Meningeome erhöhen

Parkinson: Größere Studie bestätigt Genauigkeit von Hauttest

Update Neurologie